CLL/SLL with del(17p)/TP53 mutation: First-line therapy...Preferred regimens…Acalabrutinib ± obinutuzumab

acalabrutinib (Calquence) is accepted for restricted use within NHSScotland....as monotherapy for the treatment of adult patients with previously untreated CLL who have a 17p deletion or TP53 mutation and in whom chemoimmunotherapy is unsuitable.